Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 02 December 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1738434

Correction: From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors

This article is a correction to:

  1. From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors

    1. Read original article
Mgane JassinMégane Jassin1Alix Block,Alix Block1,2Laury DsirontLaury Désiront1Louise Vrancken,Louise Vrancken1,2Cline GrgoireCéline Grégoire2Frdric Baron,Frédéric Baron1,2Grgory Ehx,Grégory Ehx1,3Thi Tham NguyenThi Tham Nguyen1Jo Caers,*Jo Caers1,2*
  • 1Laboratory of Hematology, Interdisciplinary Cluster for Applied Genoproteomics Institute (GIGA) Institute, University of Liege, Liege, Belgium
  • 2Department of Hematology, University Hospital of Liege, Liege, Belgium
  • 3Walloon Excellence in Life Sciences and Biotechnology (WELBIO) Department, Walloon Excellenxe in Life Research Institute, Wavre, Belgium

A Correction on
From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors

By Jassin M, Block A, Désiront L, Vrancken L, Grégoire C, Baron F, Ehx G, Nguyen TT and Caers J (2025) Front. Immunol. 16:1626369. doi: 10.3389/fimmu.2025.1626369

There was a mistake in the caption of Figure 6 as published. Figure uncomplete (missing words, empty square without “collagen matrix, tumor organoid, hydrogel matrix, biopsy derived cells”). The corrected caption of Figure 6 appears below.

Figure 6
Diagram showing a microfluidic device connected to different biological components. Four sections labeled: collagen matrix, tumor organoid, hydrogel matrix, and biopsy-derived cells are depicted in separate compartments. Each is linked via pathways in the device. Additional labels indicate input of oxygen, nutrients, growth factors, CAR-T injection, and molecules for chemotaxis studies, demonstrating a controlled microenvironment for experimental analysis.

Figure 6. Schematic representation of using matrix coupled with microfluidic, organ-on-chip and bioprinting. Microfluidic device is composed of different channels, one to culture the spheroid or organoid with CAR-T cells while other channels can bring oxygen, nutrients, chemotaxis molecules or growth factors or can mimick blood vessels. Channels can be coupled with filters to remove debris and dead cells. This figure was generated on Biorender.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: car-t, chimeric antigen receptor T cells, solid tumor, 3D culture, tumor microenvironment, spheroid, organoid, immunotherapy

Citation: Jassin M, Block A, Désiront L, Vrancken L, Grégoire C, Baron F, Ehx G, Nguyen TT and Caers J (2025) Correction: From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors. Front. Immunol. 16:1738434. doi: 10.3389/fimmu.2025.1738434

Received: 03 November 2025; Accepted: 14 November 2025; Revised: 04 November 2025;
Published: 02 December 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Jassin, Block, Désiront, Vrancken, Grégoire, Baron, Ehx, Nguyen and Caers. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jo Caers, Sm8uQ2FlcnNAY2h1bGllZ2UuYmU=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.